Zobrazeno 1 - 7
of 7
pro vyhledávání: '"D O, Magro"'
Autor:
A C V Silva, T J Tumelero, D O Magro, D R Yamamoto, L B M Ribeiro, G S da Silva, S K Truppel, M C Vieira, P G Kotze MD- PhD
Publikováno v:
Journal of Crohn's and Colitis. 17:i957-i958
Background There is lack of epidemiological data in regard to the accurate situation of Inflammatory Bowel Disease (IBD): Crohn’s disease (CD) and ulcerative colitis (UC) in Brazil. It is known that both diseases' progression is variable and the ch
Autor:
A Z Dotti, E G Vilela, J M F Chebli, L A Chebli, D O Magro, F Steinwurz, M Argollo, N S Carvalho, J M L Parente, R S Parra, R L Perin, C Flores, E M Morsoletto, S D C Ferreira, J C Ludvig, R L Kaiser Jr, N S F Queiroz, M A G Faria, G M Nicollelli, A R Andrade, P G Kotze
Publikováno v:
Journal of Crohn's and Colitis. 17:i714-i715
Background Vedolizumab, a human monoclonal antibody that blocks integrin α4-β7, was approved for the management of Inflammatory Bowel Diseases. In real-world experience the number of patients using vedolizumab as first-line biological therapy was l
Publikováno v:
Journal of Crohn's and Colitis. 17:i587-i587
Background Inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation of the intestine, have a rising incidence and prevalence globally. The potential impact of socioeconomic inequality
Autor:
C. L. Fratta, L. V. Pinheiro, D. O. Magro, F. O. Costa, M. G. Camargo, A. P. Lima, C. A.R. Martinez, C. S.R. Coy
Publikováno v:
69a Congresso Brasileiro 27° Congresso Latinoamericano de Coloproctologia 2021.
Autor:
M. G. Camargo, M. M. Moreira, J. O. Meirelles-Santos, D. O. Magro, C. A. R. Martinez, R. F. Leal, C. S. R. Coy, M. D. L. S. Ayrizono
Publikováno v:
69a Congresso Brasileiro 27° Congresso Latinoamericano de Coloproctologia 2021.
Publikováno v:
Diabetes, obesitymetabolism. 5(5)
To assess the effect of sibutramine-assisted weight reduction program on insulin sensitivity and metabolic parameters in obese normal glucose tolerant individuals over a period of 24 weeks.A double-blind, placebo-controlled, parallel, prospective cli